Inflarx NV logo

IFRX - Inflarx NV News Story

$3.66 -0.0  -0.3%

Last Trade - 20/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £113.5m
Enterprise Value £44.2m
Revenue £n/a
Position in Universe 4717th / 6849

BUZZ-InflaRx NV: Jumps on starting late-stage trial of potential COVID-19 treatment

Mon 14th September, 2020 2:20pm
** U.S.-listed shares of biopharma company  IFRX.O  jump
10.4% to $4.12 premarket
    ** Company starts global Phase III testing, part of its
mid-to-late stage trial for experimental drug IFX-1, in severe
COVID-19-induced pneumonia patients
    ** Enrollment for trial has commenced in Netherlands and
IFRX has received regulatory approval for the Phase III trial in
Germany 
    ** IFRX plans to enroll about 360 participants in U.S., EU,
South America and other regions
    ** An interim analysis is planned after enrollment of 180
patients, with a potential for an early stop for efficacy or
futility
    ** IFX-1 is a monoclonal antibody, which blocks the
biological activity of C5a, a protein involved in progression of
a wide variety of autoimmune and other inflammatory diseases    
    ** IFRX U.S. shares down 5.8% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.